Gold/Chitosan Nanocomposites with Specific Near Infrared Absorption for Photothermal Therapy Applications

Gold/chitosan nanocomposites were synthesized and evaluated as a therapeutic agent for the photothermal therapy. Gold nanoparticles (Au NPs) with controllable optical absorption in the near infrared (NIR) region were prepared by the reaction of chloroauric acid and sodium thiosulfate. To apply these...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nanomaterials 2012-01, Vol.2012 (2012), p.1-9
Main Authors: Patel, Dhruvin, Jasinski, Jacek, Sun, Xinghua, Zhang, Guandong, Gobin, Andre M.
Format: Article
Language:English
Subjects:
Cancer
Chemical compounds
Chitosan
Gold
Nanocomposites
Pharmacology
Stability
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gold/chitosan nanocomposites were synthesized and evaluated as a therapeutic agent for the photothermal therapy. Gold nanoparticles (Au NPs) with controllable optical absorption in the near infrared (NIR) region were prepared by the reaction of chloroauric acid and sodium thiosulfate. To apply these particles to cancer therapy, the bare Au NPs were coated with chitosan (CS), O-carboxymethyl chitosan (CMCS), and a blend of CS and CMCS for utilizations in physiologic conditions. The surface properties, optical stability, and photothermal ablation efficiency on hepatocellular carcinoma cells (HepG2) and human dermal fibroblast cells (HDF) demonstrate that these gold nanocomposites have great potential as a therapeutic agent in in vitro tests. The CS-coated nanocomposites show the highest efficiency for the photo-ablation on the HepG2 cells, and the CS and CMCS blended coated particles show the best discrimination between the cancer cell and normal cells. The well-controlled NIR absorption and the biocompatible surface of these nanocomposites allow low-power NIR laser activation and low-dosage particle injection for the cancer cell treatment.
ISSN:1687-4110
1687-4129
DOI:10.1155/2012/853416